Semiquantitative Measurement of Hepatitis B Virus e Antigen by Elecsys 2010 Immunoanalyzer in Lamivudine Treated Patients.
- Author:
Do Sim PARK
1
;
Young Jin LEE
;
Ji Hyun CHO
;
Bok Hee CHOI
Author Information
1. Department of Laboratory Medicine and Institute of Wonkwang Medical Science, School of Medicine, Wonkwang University, Iksan, Korea. email@wonkwang.ac.kr
- Publication Type:Original Article
- Keywords:
Hepatitis B virus;
e Antigen;
Elecsys 2010;
DNA;
Lamivudine
- MeSH:
DNA;
Hepatitis B e Antigens;
Hepatitis B virus*;
Humans;
Lamivudine*
- From:The Korean Journal of Laboratory Medicine
2003;23(1):12-17
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: These days the Hepatitis B virus (HBV) DNA quantitation is the common tool for defining the viral replication state and antiviral therapeutic effect. However, it has a slow turn around time due to a labour intensive complex procedure. The HBeAg assay is a simple, rapid test, but it gives only qualitative information. However, Elecsys 2010 immunoanalyzer (Roche Diag-nostics GmbH, Germany) gives not only qualitative information but also semiquantitative information. So, we want to know about the clinical utility of HBeAg semiquantitation on Elecsys 2010. METHODS: HBeAg and HBV DNA were measured serially for 18 months by Elecsys 2010 and the Hybrid Capture System (HCS; Digene Corporation, Gaithersburg, USA) respectively to evaluate their general correlations (n=287) and serial-changing patterns after lamivudine treatment (n=30, 12-18 months) in 41 patients positive for HBeAg and HBV DNA. RESULTS: Positive correlation was found between the semiquantitative results of HBeAg and the quantitative results of HBV DNA (R=0.56, P<0.05). At two and five months after lamivudine treatment, significant differences (P<0.05) between HBV DNA disappearance groups (group 2, 3) and the HBV DNA remnant group (group 4) were found in the HBeAg level and a decreasing rate. The serial HBeAg and HBV DNA level and the decreasing rate showed a similar pattern in the HBV DNA disappearance groups (group 2, 3). However, a markedly delayed decreasing pattern in the HBeAg level was observed in the HBV DNA remnant group, when compared with HBV DNA. CONCLUSIONS: HBeAg semiquantitation using Elecsys 2010 would provide a cost effective, fast and valuable, and supplementary monitoring tool when the result might be reported in quantity in a dynamic range, because HBeAg semiquantitation could provide an outline of the HBV replication state HBeAg positive patients and a therapeutic predictive value in HBeAg positive, lamivudine treated patients.
